Given the important roles of FXR in NAFLD (Chao et al., 2016), we want to explore novel therapeutic effects of vidofludimus on NAFLD as an FXR ligand in addition to its anti-inflammatory function. This evidence concerns the gene NR1H4 and metabolic dysfunction-associated steatotic liver disease.